Progenics Pharmaceuticals Inc. (PGNX) Given Consensus Recommendation of "Buy" by Analysts

Progenics Pharmaceuticals Inc. (PGNX) Given Consensus Recommendation of "Buy" by Analysts


Shares of Progenics Pharmaceuticals Inc. have earned an average rating of "Buy" from the seven ratings firms that are covering the stock. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company.



from Biotech News